Diffuse alveolar hemorrhage (DAH) is bleeding that fills the tiny air sacs of the lungs, and it is a medical emergency that can rapidly progress to respiratory failure. The condition is not a single disease but rather a syndrome triggered by dozens of different disorders, from autoimmune vasculitis to heart failure to toxic drug reactions. Because the bleeding is spread across both lungs rather than localized to one spot, DAH can be difficult to recognize early, and treatment depends heavily on identifying which underlying problem is driving it.
What Happens Inside the Lungs
When blood leaks into the alveoli, the pattern of tissue damage underneath tells clinicians a great deal about the cause. Pathologists recognize three overlapping patterns. In pulmonary capillaritis, white blood cells infiltrate the walls of the lung’s smallest blood vessels, destroying them and allowing red blood cells to flood the air sacs. In bland pulmonary hemorrhage, blood and clotting material accumulate in the alveoli but the surrounding tissue is largely spared, with no significant inflammation. In diffuse alveolar damage, the walls between air sacs swell and form a coating of protein-rich material called hyaline membranes, a pattern also seen in acute respiratory distress syndrome.1Applied Radiology. Diffuse alveolar hemorrhage These three patterns guide doctors toward a cause: capillaritis points strongly toward autoimmune vasculitis, bland hemorrhage suggests a bleeding disorder or cardiac problem, and diffuse alveolar damage often implicates infections, drugs, or radiation.2Seminars in Respiratory and Critical Care Medicine. Diffuse Alveolar Hemorrhage
Autoimmune and Vasculitic Causes
The most frequent trigger for DAH is capillaritis tied to an autoimmune condition. ANCA-associated vasculitis, a group of diseases in which the immune system attacks small blood vessels, is one of the most common culprits. The antibodies involved, known as anti-neutrophil cytoplasmic antibodies, activate white blood cells that then bore into vessel walls throughout the body. When the lung capillaries are the target, blood pours into the alveoli.3PubMed Central. Update on diffuse alveolar hemorrhage and pulmonary vasculitis DAH is considered a serious complication of ANCA-associated vasculitis, and it often arrives alongside kidney inflammation, creating what is sometimes called a pulmonary-renal syndrome.4PubMed. Diffuse alveolar haemorrhage in ANCA-associated vasculitis
Anti-glomerular basement membrane disease, historically called Goodpasture disease, is another classic cause. In this condition, antibodies target a specific protein in the membranes of both the kidneys’ filtering units and the lung’s capillaries. The result is concurrent lung bleeding and rapidly progressive kidney failure, a combination that can be fatal without urgent treatment.5PubMed. Anti-glomerular basement membrane disease (Goodpasture disease): From pathogenesis to plasma exchange to IdeS The mortality associated with this syndrome is high, and early laboratory identification of the culprit antibodies can make the difference between effective intervention and irreversible organ damage.6PubMed Central. Anti-GBM pulmonary-renal syndrome: when the laboratory makes the difference
Systemic lupus erythematosus (lupus) rounds out the major autoimmune causes. DAH is one of the most feared respiratory complications of lupus, and biopsy studies in these patients have found both the inflammatory capillaritis pattern and the bland, non-inflammatory pattern, suggesting that more than one mechanism may be at work.7PubMed Central. Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies This makes lupus-related DAH particularly tricky to manage, because the treatment strategy partly depends on which tissue pattern is present.
Cardiac Causes
Not all DAH stems from immune-mediated destruction. Heart failure and mitral valve disease are the most common cardiac causes. When the left side of the heart cannot pump efficiently or a diseased mitral valve causes blood to back up into the lungs, pressure in the pulmonary veins rises. That elevated pressure can physically rupture the thin-walled capillaries in the alveoli, a process called stress failure. The bronchial circulation, which supplies the airway walls rather than the gas-exchange surfaces, also contributes to the hemorrhage.8PubMed. Diffuse Alveolar Hemorrhage in Cardiac Diseases Recognizing a cardiac cause matters because the treatment is fundamentally different from autoimmune DAH: rather than immunosuppressive drugs, these patients need heart failure management or valve repair.
Drug-Induced, Infectious, and Transplant-Related Causes
Medications and toxic exposures can also trigger DAH. Anticoagulants are the most obvious offenders, but certain chemotherapy drugs, antiplatelet agents, and even some over-the-counter medications have been implicated. In many drug-related cases, simply stopping the offending medication or reversing a coagulation problem can halt the bleeding. When drug exposure has caused enough inflammation to produce a vasculitis-like picture, corticosteroids may be needed on top of drug withdrawal.9PubMed. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis For this reason, a detailed medication history is one of the first things clinicians pursue when a patient presents with DAH.
Infections are a less commonly recognized trigger in people with healthy immune systems, but they do cause DAH. The infections most frequently responsible in otherwise healthy individuals include influenza A (particularly H1N1 strains), dengue, leptospirosis, malaria, and Staphylococcus aureus.10PubMed Central. Infectious diseases causing diffuse alveolar hemorrhage in immunocompetent patients: a state-of-the-art review In immunocompromised patients the list of infectious triggers is even longer, encompassing fungal infections and a wider range of bacterial and viral pathogens.
Hematopoietic stem cell transplantation, commonly known as bone marrow transplant, carries its own distinct risk for DAH. The conditioning regimens used to prepare the body for the transplant, especially those involving high-dose total body irradiation, damage the lung’s delicate capillaries. Delayed engraftment or graft failure significantly raises the risk, as does the use of umbilical cord blood as the graft source.11PubMed Central. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation Acute graft-versus-host disease and the medications used to prevent it may also contribute, making the cause genuinely multifactorial in this population.12PubMed. Diffuse Alveolar Hemorrhage in Hematopoietic Cell Transplantation
Recognizing the Signs
The classic triad of DAH is coughing up blood, a falling hemoglobin level, and hazy white shadows spread across both lungs on a chest X-ray or CT scan.13PubMed Central. Diffuse alveolar hemorrhage In practice, though, up to a third of patients never actually cough up visible blood, especially early on or when the bleeding is slow. Instead, they may present with worsening shortness of breath, unexplained anemia, and low oxygen levels. The chest imaging findings can look almost identical to pneumonia or fluid overload, so DAH is easily missed if it is not specifically considered.
Fever, fatigue, and chest pain often accompany the hemorrhage but are nonspecific. When DAH is caused by a systemic vasculitis, there are usually additional clues outside the lungs: joint pain, a skin rash, blood or protein in the urine, or signs of kidney impairment. These extra-pulmonary features are often the tip-off that sends clinicians down the right diagnostic path.
How Diagnosis Is Confirmed
When DAH is suspected, bronchoscopy with bronchoalveolar lavage (BAL) is typically the key step. A thin, flexible scope is passed into the airways, and sterile fluid is washed into a segment of the lung and then suctioned back. In DAH, the returned fluid is visibly bloody, and successive washes become progressively more blood-tinged rather than clearing, a finding that distinguishes true alveolar bleeding from blood that was simply in the airway. Under the microscope, the fluid contains hemosiderin-laden macrophages: immune cells that have ingested old blood products, confirming that the bleeding has been ongoing rather than caused by the scope itself.13PubMed Central. Diffuse alveolar hemorrhage
Blood tests run in parallel. Clinicians look for ANCA antibodies, anti-GBM antibodies, antinuclear antibodies (for lupus), complement levels, kidney function, and coagulation studies. The combination of BAL results, blood work, and imaging usually narrows the cause enough to begin targeted treatment. A lung biopsy is occasionally needed when the cause remains unclear, but the urgency of DAH means treatment typically starts before biopsy results come back.
Corticosteroids as the First-Line Response
Regardless of the underlying cause, high-dose corticosteroids are almost always the first drug given once DAH is recognized. The typical approach is intravenous methylprednisolone, often delivered as pulse therapy at high doses for three days, followed by a taper to an oral steroid.14PubMed Central. Corticosteroid Therapy for Diffuse Alveolar Hemorrhage with Respiratory Failure in Hematologic Malignancies: A Retrospective Cohort Study – Section: Methods The goal is to rapidly suppress the inflammatory process destroying the capillaries. In children with idiopathic pulmonary hemosiderosis, a condition that causes recurrent DAH without a clearly identified systemic disease, aggressive high-dose steroid therapy has been associated with lower odds of needing intensive care and faster recovery of hemoglobin levels.15PubMed. Aggressive corticosteroid treatment in childhood idiopathic pulmonary hemosiderosis with better outcome
The honest reality, though, is that corticosteroids alone are often not enough in severe or autoimmune-driven cases. When DAH has progressed to respiratory failure, systemic therapies including corticosteroids, cyclophosphamide, and rituximab have all been tried, but outcomes in critically ill patients remain poor despite these treatments.16PubMed Central. Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis That does not mean the drugs are useless. Rather, it reflects how dangerous the condition is by the time it reaches the critical care stage.
Rituximab and Escalation of Immunosuppression
For DAH caused by ANCA-associated vasculitis, rituximab has emerged as a particularly effective option. In one study comparing outcomes, rituximab was independently associated with over six times the odds of achieving complete remission at six months compared with cyclophosphamide. That advantage held even among the sickest patients, including those on mechanical ventilation.17PubMed. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes Rituximab works by depleting the B cells that produce the harmful ANCA antibodies, effectively cutting off the supply of the immune weapon causing the vessel damage.
Cyclophosphamide remains in the treatment arsenal, particularly for severe or life-threatening presentations, and is often started alongside steroids while awaiting rituximab’s slower onset. The choice between the two depends on the specific diagnosis, the patient’s kidney function, and how quickly they are deteriorating.
Plasmapheresis and ECMO for Critical Cases
When autoantibodies are directly driving the bleeding, plasmapheresis (also called therapeutic plasma exchange) can physically remove those antibodies from the bloodstream. In anti-GBM disease, where pathogenic antibodies are the clear cause, plasma exchange is considered essential. In ANCA-associated vasculitis with DAH, one study found that the pulmonary hemorrhage resolved in all 20 patients treated with plasmapheresis, requiring an average of about six sessions. Among those who also had kidney involvement, half were discharged with improved kidney function.18PubMed. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis Prompt initiation of plasma exchange alongside aggressive immunosuppressive therapy can be lifesaving for the lung component of these diseases.19PubMed Central. Use of Plasmapheresis and Immunosuppressants to Treat Diffuse Alveolar Hemorrhage in a Patient with Granulomatosis with Polyangiitis
For patients whose lungs fail despite all of these measures, extracorporeal membrane oxygenation (ECMO) serves as a bridge. ECMO takes blood out of the body, adds oxygen and removes carbon dioxide through an artificial membrane, then pumps it back. It does not treat DAH directly. Instead, it keeps the patient alive and oxygenated while immunosuppressive therapies take time to work.20PubMed Central. ECMO Rescue Therapy in Diffuse Alveolar Haemorrhage: A Case Report with Review of Literature Using ECMO in DAH is tricky because the standard approach involves anticoagulation, which could worsen lung bleeding, but case reports describe successful outcomes when it is initiated early in patients with refractory respiratory failure.21PubMed. Early initiation of extracorporeal membrane oxygenation (ECMO) in emergency department to rescue severe diffuse alveolar hemorrhage
Complement-Targeted Therapy and Newer Approaches
When standard immunosuppressive regimens and plasma exchange are not enough, complement-targeted biologics represent a newer option. Eculizumab, a monoclonal antibody that blocks a key step in the complement cascade (the immune system’s amplification pathway for inflammation), has shown efficacy in lupus-related DAH that is refractory to conventional treatment. By preventing the formation of the terminal complement complex, eculizumab reduces both the inflammatory signaling and the direct endothelial injury that fuels alveolar hemorrhage. It has been used with success in cases that overlap with thrombotic microangiopathy and catastrophic antiphospholipid syndrome, conditions where the complement system is a central driver of disease.22CHEST. A Rare Concurrence of Diffuse Alveolar Hemorrhage, Atypical Hemolytic Uremic Syndrome, and Lupus Nephritis in Systemic Lupus Erythematosus – Section: DISCUSSION These biologic therapies are not yet standard of care for DAH broadly, but they are expanding the toolkit for patients who do not respond to steroids, cyclophosphamide, or rituximab.
DAH in Children
The causes of DAH in children overlap with adults but skew differently. Idiopathic pulmonary hemosiderosis (IPH), a condition where repeated alveolar bleeding occurs without an identifiable systemic disease, is the most distinctive pediatric cause. The average age at diagnosis is around five years. Children typically present with anemia and worsening lung infiltrates; coughing up blood is present in many but not all cases. In one large series of 105 children with IPH treated initially with glucocorticoids, 102 survived.23PubMed Central. Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients
Relapse is the central challenge. Most children experience at least one recurrence after the initial episode, and the triggers for flare-ups include respiratory tract infections, reductions in steroid dose, and irregular use of medication. A history of allergies may also predispose children to relapse.24PubMed Central. Clinical features and risk factors for recurrence of idiopathic pulmonary hemosiderosis in children – Section: RESULTS Despite these relapses, the long-term picture is more hopeful than the acute severity of DAH might suggest. One long-term observational study of pediatric DAH identified two broad clinical course patterns: roughly a quarter of children followed a single-episode or low-relapse course with favorable outcomes, while the majority had a multicyclic course with repeated flares. Even among the multicyclic group, most were able to lead normal lives over many years, though a small subset experienced progressive respiratory impairment.25American Journal of Respiratory and Critical Care Medicine. B105-11 The Clinical Course Of Pediatric Diffuse Alveolar Hemorrhage Syndrome, Through A Long-term Observation
Long-Term Outcomes and Relapse Patterns in Adults
Adult survivors of DAH face a variable long-term picture depending on the underlying cause and the severity of the initial episode. In ANCA-associated vasculitis, one single-center study found that after the acute episode, about a quarter of patients relapsed over a median follow-up of ten months, while just over half achieved remission. About a quarter required mechanical ventilation during their acute illness, and roughly one in six died. Chronic kidney disease was the most common form of lasting morbidity, affecting about one in five survivors.26Rheumatology. E078 Long term outcomes of diffuse alveolar haemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: a single centre study
Lung function after DAH does not always return to normal. A study of patients with lupus and vasculitis who survived DAH found abnormalities on pulmonary function testing in the majority, with some developing an obstructive pattern (airflow limitation) and others a restrictive pattern (reduced lung volumes).27ReumatologÃa ClÃnica. Chronic Respiratory Dysfunction Due to Diffuse Alveolar Hemorrhage in Patients With Systemic Lupus Erythematosus and Primary Vasculitis – Section: Results That said, no patients in that study ended up requiring long-term supplemental oxygen, suggesting that while lung function changes are common, severe chronic respiratory disability is less so. The biggest ongoing risk for most survivors is kidney damage from the same vasculitic process that attacked the lungs, which underscores why treatment strategies target the entire disease rather than the lungs alone.
When DAH Is Hard to Pin Down
One of the practical frustrations with DAH is that, in the acute setting, the cause is not always obvious. A patient arrives short of breath with bilateral hazy infiltrates, and the initial differential includes pneumonia, fluid overload, acute respiratory distress syndrome, and DAH. Hemoptysis, when present, is the strongest clue, but its absence does not rule DAH out. Falling hemoglobin in a patient with new bilateral infiltrates and no other obvious source of blood loss should prompt suspicion. The bronchoscopy and lavage described earlier are what clinch the diagnosis, but even after confirming alveolar bleeding, the underlying cause sometimes takes days of blood work and clinical observation to determine.
This diagnostic uncertainty matters for treatment. Corticosteroids are generally safe to start empirically while waiting for results, but more aggressive therapies like cyclophosphamide, rituximab, or plasma exchange carry their own risks and need a reasonably confident diagnosis to justify. In transplant patients and those with hematologic malignancies, infection must be aggressively excluded before ramping up immunosuppression, because the treatments for autoimmune DAH (suppressing the immune system) and infectious DAH (supporting the immune system) are diametrically opposed. Getting this distinction wrong can be lethal.
Drug-induced DAH is another diagnostic trap. If clinicians focus exclusively on autoimmune and infectious etiologies, they may miss that a recently started anticoagulant or chemotherapy agent is the culprit, and that simply stopping the drug might resolve the problem. A thorough medication review at presentation, including over-the-counter supplements and herbal products, is an underappreciated step in the workup.